オプションチェーンは、Axonicsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Axonicsの市場センチメントを評価します。.

Axonics (NASDAQ:AXNX) 株価情報, オプションチェーン

Axonics

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Axonics Modulation Tech

Axonics Inc

At current rates, the Company expects negligible year-over-year currency impact on the full year 2024 revenues.
Additionally, Artivion continues to expect adjusted EBITDA growth of between 28% and 34% for the full year 2024 compared to 2023 resulting in an expected range of $69 to $72 million for 2024.

News

Guidance

AORT

Artivion Narrows FY24 Revenue Outlook From $388M -$396M To $389M - $396M, Est $391.955M

Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.12 by 8.33 percent. The company reported quarterly sales of $102.638 million which beat the analyst consensus estimate of $102.001 million by 0.62 percent. This is a 20.00 percent increase over sales of $85.532 million the same period last year.

Earnings

Earnings Beats

Sprout Social Q3 2024 Adj. EPS $0.13 Beats $0.12 Estimate, Sales $102.638M Beat $102.001M Estimate

W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. The company reported quarterly sales of $121.372 million which missed the analyst consensus estimate of $122.406 million by 0.84 percent. This is a 14.77 percent decrease over sales of $142.411 million the same period last year.

Earnings Misses

W&T Offshore Q3 2024 Adj. EPS $(0.17) Beats $(0.19) Estimate, Sales $121.372M Miss $122.406M Estimate

Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.37) by 29.73 percent. The company reported quarterly sales of $26.03 million which missed the analyst consensus estimate of $34.37 million by 24.26 percent. This is a 74.03 percent increase over sales of $14.96 million the same period last year.

ACLX

Arcellx Q3 2024 GAAP EPS $(0.48) Misses $(0.37) Estimate, Sales $26.03M Miss $34.37M Estimate

Management

Natural Gas Services Group Announced The Appointment Of Ian Eckert As CFO Effective No Later Than January 5th, 2026. NGS's Current Interim CFO John Bittner Will Continue In that Role Until Mr. Eckert's Start Date

Con Edison CFO Kirk Andrews Says We Are Narrowing And Revising Our 2024 Adjusted EPS Guidance To The Upper Half Of Our Original Range

Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) sees Q4 sales of $40.000 million-45.000 million vs $50.03 million estimate.

CMBM

Cambium Networks Sees Q4 Sales $40.000M-45.000M vs $50.03M Est

SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.03 by 66.67 percent. The company reported quarterly sales of $97.400 million which beat the analyst consensus estimate of $96.647 million by 0.78 percent. This is a 23.73 percent increase over sales of $78.718 million the same period last year.

SEMR

SEMrush Hldgs Q3 2024 GAAP EPS $0.01 Misses $0.03 Estimate, Sales $97.400M Beat $96.647M Estimate

Sandstorm Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) reported quarterly sales of $44.700 which missed the analyst consensus estimate of $44.900 million by 100.00 percent. This is a 100.00 percent decrease over sales of $41.324 million the same period last year.

SAND

Sandstorm Gold Q3 Sales $44.700 Miss $44.900M Estimate

nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $56.13 million which beat the analyst consensus estimate of $55.27 million by 1.55 percent. This is a 10.85 percent increase over sales of $50.63 million the same period last year.

LASR

nLight Q3 Adj $(0.08), Inline, Sales $56.13M Beat $55.27M Estimate

Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) is looking for Q2 Adj EPS of $0.30-0.40 vs $0.27 analyst estimate. sees sales of $380.000 million-400.000 million vs $354.32 million estimate.

LITE

Lumentum Holdings Sees Q2 Adj EPS $0.30-0.40 vs $0.27 Est; Sees Sales $380.000M-400.000M vs $354.32M Est

Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.62 by 3.7 percent.

Consolidated Edison Q3 2024 Adj. EPS $1.68 Beats $1.62 Estimate

PDF Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDFS#NASDAQ">PDFS</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.20 by 25 percent. The company reported quarterly sales of $46.409 million which beat the analyst consensus estimate of $46.196 million by 0.46 percent. This is a 9.58 percent increase over sales of $42.350 million the same period last year.

PDFS

PDF Solutions Q3 2024 Adj. EPS $0.25 Beats $0.20 Estimate, Sales $46.409M Beat $46.196M Estimate

TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) affirms FY2024 sales outlook from $74.50 million-76.50 million to $74.50 million-76.50 million.

TELA

TELA Bio Affirms FY2024 Sales Guidance from $74.50M-76.50M to $74.50M-76.50M

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2025 Product sales outlook from $450.00 million-475.00 million to $450.00 million-475.00 million.

IOVA

Iovance Biotherapeutics Affirms FY2025 Product Sales Guidance from $450.00M-475.00M to $450.00M-475.00M

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) raises FY2024 sales outlook from $580.00 million-595.00 million to $620.00 million-635.00 million.

COLL

Collegium Pharmaceutical Raises FY2024 Sales Guidance from $580.00M-595.00M to $620.00M-635.00M  VS Est.625.37M

CPAY

Corpay Expects Q4 Total Revenues Of $1.04B - $1.07B, Adjusted EP Of $5.25 - $5.45

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2024 Product sales outlook from $160.00 million-165.00 million to $160.00 million-165.00 million.

Iovance Biotherapeutics Affirms FY2024 Product Sales Guidance from $160.00M-165.00M to $160.00M-165.00M

AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. This is a 33.33 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $82.68 million which missed the analyst consensus estimate of $92.83 million by 10.93 percent. This is a 10.60 percent decrease over sales of $92.48 million the same period last year.

ASLE

AerSale Q3 Adj $0.04 Misses $0.05 Estimate, Sales $82.68M Miss $92.83M Estimate

Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. The company reported quarterly sales of $7.855 million which beat the analyst consensus estimate of $4.215 million by 86.37 percent. This is a 180.74 percent increase over sales of $2.798 million the same period last year.

AMPX

Amprius Technologies Q3 2024 GAAP EPS $(0.10) Beats $(0.13) Estimate, Sales $7.855M Beat $4.215M Estimate

Top Merger Stocks Held By Fund Managers, Mid-Q3 2024

Tracking George Soros's 13F Portfolio - Q2 2024 Update

Axonics gains after win in trial in patent dispute with Medtronic

Piper Sandler analyst Adam Maeder maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) today and set a price target...

Piper Sandler Keeps Their Hold Rating on Axonics Modulation Technologies (AXNX)

Deals this week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and more

Axonics gets regulatory nod for fourth-generation rechargeable SNM system in Australia

Axonics gains after Boston Scientific says it will end use of Coaptite on Nov. 1

RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) on October 8 and set a...

Axonics Modulation Technologies (AXNX) Receives a Hold from RBC Capital

Catalyst Watch: Earnings blitz, Fed speakers, and notable healthcare conferences

Axonics' Market Growth Strengthens Boston Scientific's Future

AAPL

ALTM

AMED

ANRO

ANSS

ARMK

ASAN

AXNX

AZNCF

BABA

BABAF

BATL

BIOX

BKNG

BLCO

BOOM

BYON

CACI

CALM

CAMRF

CBOE

CFLT

COST

CPRI

CTLT

DENN

ETON

FFIE

FLUT

GOOG

GOOGL

INFN

JDCMF

JNPR

LBRDA

LBRDB

LBRDK

LBRDP

LOGI

LSXMA

LSXMB

LSXMK

MEDP

MMSI

MNDY

NONOF

OKTA

OMIC

PLTK

PYTCY

QCOM

RIVN

RVNC

SATS

SMAR

SRCL

SRDX

STZHF

TEAM

TMUS

TSLA

UBER

VVPR

WHLR

Press Releases

Axonics Provides Update on Inter Partes Review Proceedings

Axonics Stockholders Approve Merger Agreement with Boston Scientific

Boston Scientific Announces Results for First Quarter 2024

Axonics Reports First Quarter 2024 Financial Results

Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

Axonics Reports Second Quarter 2024 Financial Results

Axonics Prevails in Patent Infringement Lawsuit with Medtronic

Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

Comments

Axonics

Axonics (AXNX) オプション

Axonics (NASDAQ:AXNX) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル